ImmunoGen (NASDAQ:IMGN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a research note issued to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on IMGN. Piper Sandler restated a neutral rating and set a $31.00 price target (up […]

Related Keywords

Blackrock ,New Zealand General ,New Zealand ,Wellington ,William Blair ,Theresa Wingrove ,Piper Sandler ,Securities Exchange Commission ,Immunogen Inc ,Barclays ,Jefferies Financial Group ,Wellington Management Group ,Blackrock Inc ,Vanguard Group Inc ,Free Report ,Financial Group ,Exchange Commission ,Street Corp ,Management Group ,Get Free Report ,Immunogen Daily ,Immunogen ,Nasdaq Imgn ,Imgn ,Medical ,45253h10 ,Initiated Coverage ,Stocknews Com ,